Bristol-Myers Squibb (NYSE:BMY) Shares Sold by WealthTrust Axiom LLC

WealthTrust Axiom LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 112,935 shares of the biopharmaceutical company’s stock after selling 389 shares during the quarter. Bristol-Myers Squibb comprises about 1.9% of WealthTrust Axiom LLC’s holdings, making the stock its 11th largest holding. WealthTrust Axiom LLC’s holdings in Bristol-Myers Squibb were worth $5,795,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Certuity LLC increased its stake in Bristol-Myers Squibb by 55.9% during the fourth quarter. Certuity LLC now owns 40,729 shares of the biopharmaceutical company’s stock worth $2,090,000 after acquiring an additional 14,606 shares during the last quarter. Norden Group LLC increased its stake in Bristol-Myers Squibb by 7.8% during the fourth quarter. Norden Group LLC now owns 10,633 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 773 shares during the last quarter. Penobscot Investment Management Company Inc. increased its stake in Bristol-Myers Squibb by 3.4% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 18,437 shares of the biopharmaceutical company’s stock worth $946,000 after acquiring an additional 600 shares during the last quarter. Kestra Private Wealth Services LLC increased its stake in Bristol-Myers Squibb by 9.4% during the fourth quarter. Kestra Private Wealth Services LLC now owns 152,909 shares of the biopharmaceutical company’s stock worth $7,846,000 after acquiring an additional 13,098 shares during the last quarter. Finally, Ledyard National Bank increased its stake in Bristol-Myers Squibb by 1.3% during the fourth quarter. Ledyard National Bank now owns 31,183 shares of the biopharmaceutical company’s stock worth $1,600,000 after acquiring an additional 393 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday. Barclays lowered their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Stock Down 1.0 %

Bristol-Myers Squibb stock traded down $0.46 during midday trading on Tuesday, reaching $44.18. The company’s stock had a trading volume of 10,247,916 shares, compared to its average volume of 15,899,321. The business has a 50-day simple moving average of $50.93 and a 200-day simple moving average of $51.02. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a fifty-two week low of $43.97 and a fifty-two week high of $69.10. The company has a market cap of $89.56 billion, a P/E ratio of -14.38, a P/E/G ratio of 15.47 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the previous year, the firm earned $2.05 earnings per share. The business’s revenue was up 4.7% compared to the same quarter last year. On average, research analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.43%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.